The Amyloidosis Channel is supported with funding from Prothena (Silver).
The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
COMy 2023 | Novel treatment approaches being explored in amyloidosis: immunotherapeutic agents & venetoclax
Shaji Kumar, MD, Mayo Clinic, Rochester, MN, briefly discusses promising treatment avenues being explored in amyloidosis, highlighting the potential application of CAR-T cells and bispecific antibodies, and further comments on the off-label use of venetoclax in this disease. This interview took place at the 9th World Congress on Controversies in Multiple Myeloma (COMy) 2023, held in Paris, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Research funding for clinical trials to the institution: Abbvie, Amgen, Allogene, BMS, Carsgen, GSK, Janssen, Roche-Genentech, Takeda, Regeneron
Consulting/Advisory Board participation: (with no personal payments) Abbvie, BMS, Janssen, Roche-Genentech, Takeda, Pfizer, Loxo Oncology, K36, Sanofi, ArcellX, Beigene, and (with personal payment) Oncopeptides, Antengene
